PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and
low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University